WALTHAM, Mass., April 13, 2018 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax," the "Company" or "we")
(Nasdaq:SNDX), a clinical stage biopharmaceutical company
developing an innovative pipeline of cancer therapies, today
announced twelve oral and poster presentations at the upcoming
American Association for Cancer Research (AACR) Annual Meeting
being held April 14-18, 2018 in
Chicago, Illinois.
Details on Presentations
Oral Presentations:
Title: Safety, efficacy, and immune correlates of
alternative doses and schedules of entinostat combined with
pembrolizumab in patients with advanced solid tumors - results from
SNDX-275-0141 phase I trial
Presenter: Anthony W.
Tolcher, M.D.
Category: Clinical Trials
Session: Biomarkers in Immuno-oncology
Abstract Number: CT179
Location: N Hall C - McCormick Place North (Level
1)
Date and Time: Tuesday April 17, 2018; 3:50 PM - 4:05 PM C.T.
Title: VTP-50469 is a novel, orally-available
Menin-MLL1 targeted inhibitor effective against MLL-Rearranged and
NPM1-mutant leukemia
Presenter: Andrei V.
Krivtsov, PhD
Category: Experimental and Molecular Therapeutics
Session: Early Novel Drug Development
Abstract Number: 4958
Location: McCormick Place South, Room S102 (Level
1)
Date and Time: Tuesday April 17, 2018; 3:50 PM - 4:05 PM C.T.
Title: Entinostat transforms the suppressive tumor
microenvironment of breast cancer and promotes survival and
anti-responses when combined with checkpoint inhibition
Presenter: Evanthia T. Roussos
Torres, MD, PhD
Category: Immunology
Session: Epigenetic and Metabolic Regulation of Cancer
Immunity
Abstract Number: 4965
Location: McCormick Place West, Room W196 (Level 1)
Date and Time: Tuesday April 17, 2018; 3:50 PM - 4:05 PM C.T.
Selected Poster Presentations:
Title: Enhanced anti-tumor activity of the combination of
entinostat and NKTR214 in renal and colon cancer tumor
models
Category: Tumor Biology
Session: Role of the Innate Immune System in
Tumorigenesis
Abstract Number: 123
Location: McCormick Place South, Exhibit Hall A, Poster
Section 5
Date and Time: Sunday April 15, 2018; 1:00 PM - 5:00 PM C.T.
Title: Epigenetic reprogramming of the tumor
microenvironment by Entinostat increases tumor sensitivity to
multivalent immunotherapy combinations with an IL-15 superagonist
plus vaccine or immune checkpoint blockade
Category: Immunology
Session: Modifiers of the Tumor Microenvironment 2
Abstract Number: 1740
Location: McCormick Place South, Exhibit Hall A, Poster
Section 33
Date and Time: Monday April 16, 2018; 8:00 AM - 12:00 PM C.T.
Title: Epigenetic modulation of the tumor
microenvironment enhances immune checkpoint efficacy in a murine
model of pancreatic cancer
Category: Immunology
Session: Modifiers of the Tumor Microenvironment 2
Abstract Number: 1746
Location: McCormick Place South, Exhibit Hall A, Poster
Section 33
Date and Time: Monday April 16, 2018; 8:00 AM - 12:00 PM C.T.
Title: Activity of entinostat alone and in combination
with cisplatin in a panel of low passage adenoid cystic carcinoma
patient-derived xenograft (PDX) models
Category: Tumor Biology
Session: Translational Therapeutics in Cancer Models
2
Abstract Number: 2146
Location: McCormick Place South, Exhibit Hall A, Poster
Section 7
Date and Time: Monday April 16, 2018; 1:00 PM - 5:00 PM C.T.
Title: Antitumor activity of HDAC inhibition in bladder
cancer mouse models correlates with enhanced immune
response
Category: Immunology
Session: Immune Mechanisms Invoked by Therapies 1
Abstract Number: 2748
Location: McCormick Place South, Exhibit Hall A, Poster
Section 33
Date and Time: Monday April 16, 2018; 1:00 PM - 5:00 PM C.T.
Title: Overcoming resistance to DNA targeted agents by
epigenetic activation of Schlafen 11 (SLFN11) expression with class
I histone deacetylase inhibitors
Category: Molecular and Cellular Biology/Genetics
Session: Late-Breaking Research: Molecular and Cellular
Biology / Genetics 2
Abstract Number: LB-244
Location: McCormick Place South, Exhibit Hall A, Poster
Section 45
Date and Time: Tuesday April 17, 2018; 8:00 AM - 12:00 PM C.T.
Title: Pediatric Preclinical Testing Consortium
evaluation of the menin inhibitor, VTP-50469, against xenograft
models of MLL-rearranged infant acute lymphoblastic
leukemia
Category: Tumor Biology
Session: Pediatrics 2: Preclinical Therapies,
Resistance, and Stem Cells
Abstract Number: 3187
Location: McCormick Place South, Exhibit Hall A, Poster
Section 7
Date and Time: Tuesday April 17, 2018; 8:00 AM - 12:00 PM C.T.
Title: Histone deacetylase inhibitor, Entinostat enhances
the tumor specific immune response by generating T-cell central
memory in the TME
Category: Immunology
Session: Immunomodulatory Agents and Interventions
1
Abstract Number: 3761
Location: McCormick Place South, Exhibit Hall A, Poster
Section 32
Date and Time: Tuesday April 17, 2018; 8:00 AM - 12:00 PM C.T.
Title: Manipulating the breast tumor microenvironment
with histone deacetylase inhibitors for more robust and durable T
cell responses
Category: Immunology
Session: Immunomodulatory Agents and Interventions
2
Abstract Number: 4700
Location: McCormick Place South, Exhibit Hall A, Poster
Section 33
Date and Time: Tuesday April 17, 2018; 1:00 PM - 5:00 PM C.T.
All accepted abstracts will be published in the
2018 Proceedings of the AACR. Session information is
available online via the Annual Meeting Itinerary Planner through
the AACR website at www.aacr.org.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical
company developing an innovative pipeline of cancer therapies. The
Company is developing its lead product candidate, entinostat, a
once-weekly, oral, small molecule, class I HDAC inhibitor, in
combination with exemestane and several approved PD-1/PD-L1
antagonists. The Company's pipeline also includes SNDX-6352, a
monoclonal antibody that blocks the colony stimulating factor 1
(CSF-1) receptor, as well as a portfolio of potent and selective
inhibitors targeting the binding interaction of Menin with MLLr.
For more information, please visit www.syndax.com or follow the
Company on Twitter and LinkedIn.
Syndax's Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend," "believe" and similar expressions (as well as
other words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Syndax's expectations
and assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. Forward-looking statements contained in this press
release include, but are not limited to, statements about the
progress, timing, clinical development and scope of clinical trials
and the reporting of clinical data for Syndax's product candidates,
and the potential use of our product candidates to treat various
cancer indications. Many factors may cause differences between
current expectations and actual results including unexpected safety
or efficacy data observed during preclinical or clinical studies,
clinical trial site activation or enrollment rates that are lower
than expected, changes in expected or existing competition, changes
in the regulatory environment, failure of Syndax's collaborators to
support or advance collaborations or product candidates and
unexpected litigation or other disputes. Other factors that may
cause Syndax's actual results to differ from those expressed or
implied in the forward-looking statements in this press release are
discussed in Syndax's filings with the U.S. Securities and Exchange
Commission, including the "Risk Factors" sections contained
therein. Except as required by law, Syndax assumes no obligation to
update any forward-looking statements contained herein to reflect
any change in expectations, even as new information becomes
available.
Syndax Contacts
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
Tel 212.600.1902
SNDX-G
View original
content:http://www.prnewswire.com/news-releases/syndax-to-present-at-the-2018-american-association-for-cancer-research-annual-meeting-300629265.html
SOURCE Syndax Pharmaceuticals